Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 53
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
10/22/2008
 
First Published:
7/23/2004
1.
Phase III Randomized Study of Docetaxel With or Without Gefitinib in Patients With Metastatic or Locally Recurrent Squamous Cell Carcinoma of the Head and Neck
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
NCI
ECOG-E1302
E1302, NCT00088907
2.
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Other
IRB 13362B
NCT00117572
Last Modified:
10/17/2008
 
First Published:
12/22/2005
3.
Phase III Study of Radiotherapy and Amifostine OR Neoadjuvant Induction Chemotherapy Followed By Consolidation Chemoradiotherapy and Amifostine in Children With Newly Diagnosed Nasopharyngeal Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and under
NCI
COG-ARAR0331
ARAR0331, NCT00274937
4.
Nutrition and Resistance Training in Head and Neck Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care, Treatment
Active
21 and over
Other
080219
NCT00696553
5.
Radiotherapy, Cetuximab, and Injections of TNFeradeâ„¢ Biologic for Elderly or Frail Patients With Head and Neck Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
Over 18
Pharmaceutical / Industry
UCIRB #14735B
GV-001.010 (TNF-ELF), NCT00496236
6.
A Study of TNFeradeâ„¢ Biologic With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Pharmaceutical / Industry
UCIRB #14733B
GV-001.011 (TNF-CORE), NCT00496535
7.
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Other
07-069
NCT00570674
8.
A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
12652A
NCT00203905
9.
Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
OSU-0482
NCT00293579
10.
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
H-26154 (GCC 0442)
CA225092, NCT00343083
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute